Clinical Trial

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Study acronym: BROADEN2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-01
notable Trial sites expanded: 61 -> 67 locations 2026-05-19
notable Trial sites expanded: 49 -> 61 locations 2026-04-24
notable Trial sites expanded: 31 -> 49 locations 2026-04-09
Trial Details
NCT Number NCT07217015
Lead Sponsor Kymera Therapeutics, Inc.
Conditions Atopic Dermatitis
Enrollment 200 participants
Start Date 2025-11-24
Primary Completion 2027-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-30